SOLACI regrets the passing of Dr. Leandro Martínez Riera

Dr. Leandro Martínez Riera

Dear members of the SOLACI community,

It is with profound grief and sorrow that we inform the passing of our dear friend Dr. Leandro Martínez Riera, director of the ProEducar newsletter. Leandro was a tireless collaborator of SOLACI’s and its educational program. He was an outstanding man who lived by the highest moral and professional standards, the likes of which are not easily found nowadays. We extend our deepest condolences to his wife, Alejandra, his daughter, Milagros, and his son, Máximo.

ProEducar – SOLACI

More articles by this author

The El Salvador 2024 Sessions are coming soon

The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Virtual Event SOLACI-Medtronic | The Visible Heart Lab

We invite you to participate in a new virtual activity organized in collaboration with Medtronic, focused on "The Visible Heart Lab" and dedicated to...

SOLACI-CACI 2024 – Presentations day 3

Discover the highlights of the third day of activities of  SOLACI-CACI 2024 Congress, held from August 7 to 9 at the Hilton Hotel in Buenos Aires, Argentina. Dr....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...